The
healthcare company's global sales total for the three-month period came to
$3.72 billion (2.32 billion pounds), an increase of nearly six percent when
excluding the impact of foreign exchange.
During the quarter, Abbott was able to announce a number of new product launches and strategic partnerships to bolster its portfolio, while reporting positive clinical trial data on key therapies such as Humira.
As a result of this performance, the firm has raised its ongoing earnings-per-share outlook for the 2012 full year to between $5.00 and $5.10, up from $4.95 to $5.05.
During the quarter, Abbott was able to announce a number of new product launches and strategic partnerships to bolster its portfolio, while reporting positive clinical trial data on key therapies such as Humira.
As a result of this performance, the firm has raised its ongoing earnings-per-share outlook for the 2012 full year to between $5.00 and $5.10, up from $4.95 to $5.05.
Miles White, chairman and chief executive officer for Abbott, said: "We remain focused on the process of separating Abbott into two leading healthcare companies, which remains on track to be completed by the end of the year."
The group revealed last month that the planned split will result in the creation of an independent research-based pharmaceutical company called AbbVie, while the Abbott name will be retained by the diversified medical products division.
